TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15219652

Group type: EXPERIMENTAL
Intervention: Parental loss by death (n=9)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No parental loss or separation (n=38)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Temporary separation from one or both parents (n=10)
Number of subjects: 57
Study: 12365877

Group type: EXPERIMENTAL
Intervention: High lifetime panic-agoraphobic spectrum symptom scores
Number of subjects: 66

Group type: COMPARATOR
Intervention: Low lifetime panic-agoraphobic spectrum symptom scores
Number of subjects: 66
Study: 11693763

Group type: EXPERIMENTAL
Intervention: Imidapril (n = 13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amlodipine (n = 12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 25
Study: 9307551

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 0
Study: 8325064

Group type: COMPARATOR
Intervention: Nebulized morphine 0 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulized morphine 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulized morphine 4 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulized morphine 10 mg
Number of subjects: 8
Study: 2876127

Group type: EXPERIMENTAL
Intervention: Pindolol 1% eye drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metipranolol 0.6% eye drops
Number of subjects: 0
Study: 30539864

Group type: EXPERIMENTAL
Intervention: Concurrent 125I implantation and chemotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Chemotherapy-only
Number of subjects: 82
Study: 27058904

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25027638

Group type: EXPERIMENTAL
Intervention: Protease inhibitors in HIV-positive patients with lipodystrophy syndrome
Number of subjects: 267

Group type: COMPARATOR
Intervention: HIV-negative patients without lipodystrophy syndrome
Number of subjects: 267

Group type: COMPARATOR
Intervention: HIV-positive patients not using protease inhibitors
Number of subjects: 267

Group type: COMPARATOR
Intervention: HIV-positive patients treated with protease inhibitors but without posterior ankle pain
Number of subjects: 267
Study: 22154039

Group type: EXPERIMENTAL
Intervention: Contingency management-family engagement (CM-FAM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual services (US)
Number of subjects: 104
Study: 20547525

Group type: EXPERIMENTAL
Intervention: Postpartum screening for type 2 diabetes (T2DM) via oral glucose tolerance tests (OGTTs)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Postpartum screening for T2DM by primary care providers (PCPs)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Reminder letters for facilitating screening
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Importance of screening for T2DM
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Responsibility for screening
Number of subjects: 223
Study: 18713922

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TDN) 30 (21 mg nicotine) patches administered 1 h before induction of anesthesia and for two additional days after surgery
Number of subjects: 97

Group type: COMPARATOR
Intervention: Inert (sham) patches administered 1 h before and for 2 days after surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups (nicotine and control)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Nicotine group
Number of subjects: 97
Study: 16296612

Group type: EXPERIMENTAL
Intervention: 2% SDBS ointment
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2% metronidazole ointment
Number of subjects: 62
Study: 12675669

Group type: EXPERIMENTAL
Intervention: 10 mg glibenclamide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 mg/kg diazoxide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10355239

Group type: EXPERIMENTAL
Intervention: Relaxed decision criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard decision criteria
Number of subjects: 0
Study: 10182204

Group type: EXPERIMENTAL
Intervention: Batch sampling method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community endpoint means stability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temporal variation
Number of subjects: 0
Study: 2022044

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dipyridamole echocardiography
Number of subjects: 35
Study: 31770068

Group type: EXPERIMENTAL
Intervention: HPV vaccine Lot 1
Number of subjects: 3689

Group type: EXPERIMENTAL
Intervention: HPV vaccine Lot 2
Number of subjects: 3689

Group type: EXPERIMENTAL
Intervention: HPV vaccine Lot 3
Number of subjects: 3689
Study: 31268126

Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage (full dose, n=25)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage (one-half dose, n=35)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Broccoli sprout beverage (one-fifth dose, n=55)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo beverage (n=55)
Number of subjects: 170
Study: 28146026

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional neck exercises
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 75
Study: 26102255

Group type: EXPERIMENTAL
Intervention: External focus (EX)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Broad internal focus (B-IN)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Narrow internal focus (N-IN)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 68
Study: 24553678

Group type: EXPERIMENTAL
Intervention: Intramuscular injections into the subscapularis muscle
Number of subjects: 36

Group type: COMPARATOR
Intervention: Scapulothoracic bursa injections
Number of subjects: 36
Study: 23107861

Group type: EXPERIMENTAL
Intervention: Meaning of Life Intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 19751376

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Caffeine (combined treatment plus prophylaxis)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Theophylline and Caffeine (both)
Number of subjects: 70
Study: 17521032

Group type: EXPERIMENTAL
Intervention: 100 microg of hydrofluoroalkane beclomethasone dipropionate via the Neohaler (NH)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 100 microg of hydrofluoroalkane beclomethasone dipropionate via the AeroChamber Plus (AP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 400 microg of hydrofluoroalkane beclomethasone dipropionate via the Neohaler (NH)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 400 microg of hydrofluoroalkane beclomethasone dipropionate via the AeroChamber Plus (AP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: In vitro fine particle dose for Neohaler (NH) with 100-microg formulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: In vitro fine particle dose for AeroChamber Plus (AP) with 100-microg formulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: In vitro fine particle dose for Neohaler (NH) with 50-microg formulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: In vitro fine particle dose for AeroChamber Plus (AP) with 50-microg formulation
Number of subjects: 17
Study: 15209624

Group type: EXPERIMENTAL
Intervention: Aspirin + eradication (omeprazole 20 mg b.i.d. and amoxicillin 500 mg q.i.d. for 2 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aspirin + placebo eradication
Number of subjects: 32
Study: 11685360

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (16 physiotherapeutic exercises for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Knee splint (special resistance-controlled knee splint for 15 min three times daily)
Number of subjects: 40
Study: 9588444

Group type: EXPERIMENTAL
Intervention: ICA512 autoantibodies
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: phogrin autoantibodies
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intramolecular epitope spreading
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Decrease in number of epitopes recognized
Number of subjects: 152
Study: 7975843

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ) virus at age 4-8 months (medium dose: 40,000 p.f.u. and high dose: 150,000 p.f.u.)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Schwarz (SW) virus at age 9-12 months (standard dose: 5000 p.f.u.)
Number of subjects: 362
Study: 2644342

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clomipramine 75 mg/day
Number of subjects: 30
Study: 800970

Group type: EXPERIMENTAL
Intervention: tolmetin (1600 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: phenylbutazone (400 mg/day)
Number of subjects: 24
Study: 31310038

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided axillary vein access
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cephalic vein access
Number of subjects: 240
Study: 28619301

Group type: EXPERIMENTAL
Intervention: Gua sha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocollator-based hot pack therapy (active control)
Number of subjects: 0
Study: 24801108

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (WED)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neutral writing (control)
Number of subjects: 41
Study: 23860345

Group type: EXPERIMENTAL
Intervention: D‐MPH‐ER 30 mg
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: D‐MPH‐ER 20 mg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 21722499

Group type: EXPERIMENTAL
Intervention: Abatacept approximately 10 mg/kg
Number of subjects: 108
Study: 19801244

Group type: EXPERIMENTAL
Intervention: Conventional irrigation with NaviTip needles (20 mL NaOCl and EDTA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional irrigation with NaviTip needles + EndoActivator (20 mL NaOCl and EDTA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Irrigation with EndoVac system (43 mL NaOCl and EDTA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with saline solution (43 mL)
Number of subjects: 60
Study: 16677241

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study: 15093801

Group type: EXPERIMENTAL
Intervention: Peer sexual health education intervention
Number of subjects: 416
Study: 10779265

Group type: EXPERIMENTAL
Intervention: High inositol formula (2500 micromol/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower inositol formula (710 and 242 micromol/L)
Number of subjects: 0
Study: 9313749

Group type: EXPERIMENTAL
Intervention: Insulin therapy (ultralente)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy (gliclazide)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 8
Study: 8376739

Group type: EXPERIMENTAL
Intervention: Serum vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Recombinant vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined regimen (serum and recombinant vaccines)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three doses of serum-derived vaccine
Number of subjects: 100
Study: 3511409

Group type: EXPERIMENTAL
Intervention: K‐canrenoate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 90
Study: 31242333

Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tunnel technique (TUN)
Number of subjects: 19
Study: 28667207

Group type: EXPERIMENTAL
Intervention: Multidimensional intervention based on individual patient-reported outcomes (PROs) including electronic assessment of PRO, creation of a case vignette, and treatment suggestions from expert panel discussions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual supportive treatment.
Number of subjects: 0
Study: 26137844

Group type: EXPERIMENTAL
Intervention: SMS-text adherence support intervention
Number of subjects: 15
Study: 24065808

Group type: EXPERIMENTAL
Intervention: Acrysof Natural IQ IOLs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adapt‐AO IOLs
Number of subjects: 30
Study: 21735983

Group type: EXPERIMENTAL
Intervention: Menopausal symptoms awareness
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Knowledge of means to mitigate symptoms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Knowledge of soya and soya-based supplements
Number of subjects: 100
Study: 19663113

Group type: EXPERIMENTAL
Intervention: Fluocinonide 0.1% cream
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Clobetasol 0.05% cream
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Halobetasol 0.05% cream
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 5
Study: 16784972

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 2659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2659
Study: 15121348

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Patients taking ADs
Number of subjects: 533

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 533
Study: 11245352

Group type: EXPERIMENTAL
Intervention: Multiple dose IVIG treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Single dose MG treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: No IVIG treatment (Control group)
Number of subjects: 61
Study: 9399606

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 17

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 17
Study: 8181191

Group type: EXPERIMENTAL
Intervention: 400 mg ketoconazole orally once daily for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole orally once daily for 4 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched placebo orally once daily for 4 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam administered on day 4
Number of subjects: 9
Study: 3371079

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg 3-times daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg single daily dose)
Number of subjects: 30
Study: 30565543

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Dementing illnesses
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: No cognitive impairment
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Documented diagnosis of dementia
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: Treatment for dehydration, electrolyte disturbances, urinary tract infections, contusions, and bone fractures
Number of subjects: 1469
Study: 26525521

Group type: EXPERIMENTAL
Intervention: Ticagrelor (initial dose of 180 mg and maintenance dose of 90 mg twice daily, n = 149)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clopidogrel (initial dose of 300 mg and maintenance dose of 75 mg once daily, n = 151)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 300
Study: 23877306

Group type: EXPERIMENTAL
Intervention: Sublingual midazolam 0.25 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sublingual dexmedetomidine 1.5 µg/kg
Number of subjects: 100
Study: 22275399

Group type: EXPERIMENTAL
Intervention: 30 μg HA 2009 H1N1 vaccine
Number of subjects: 192

Group type: COMPARATOR
Intervention: 15 μg HA 2009 H1N1 vaccine
Number of subjects: 192
Study: 20737140

Group type: EXPERIMENTAL
Intervention: Oral ibandronate (2.5 mg daily, 20 mg intermittent)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (0.5 mg, 1 mg quarterly)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pooled analysis of ibandronate
Number of subjects: 2
Study: 18276620

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: MFP
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: E/Ea
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Elevated NT-proBNP and E/Ea >15
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and E/Ea
Number of subjects: 228
Study: 16322625

Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 0
Study: 11437014

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Imipramine (200-300 mg)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 275
Study: 10093625

Group type: COMPARATOR
Intervention: Epirubicin (at doses equivalent to doxorubicin)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Epirubicin (higher doses)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 13
Study: 8063233

Group type: EXPERIMENTAL
Intervention: CA 125 (> 65 U/ml)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: CA 125 (> 35 U/ml)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound (US)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Combination of US and CA 125 (> 65 U/ml)
Number of subjects: 388
Study: 2899510

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg b.d.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indenolol 60 mg o.d.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tyramine (i.v. boluses of 1-6 mg)
Number of subjects: 6
Study: 30898974

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST) immediately following the encoding part of the memory task
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control version of the TSST that did not induce a stress response
Number of subjects: 69
Study: 29187126

Group type: EXPERIMENTAL
Intervention: Simulation-based training program
Number of subjects: 86
Study: 23299761

Group type: EXPERIMENTAL
Intervention: D/E only
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: D/E plus fenofibrate
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: D/E plus niacin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: All interventions (D/E, D/E plus fenofibrate, D/E plus niacin)
Number of subjects: 107
Study: 20932669

Group type: EXPERIMENTAL
Intervention: Early radiotherapy (RT) with chemotherapy (fluorouracil 375 mg/m(2)/day and leucovorin 20 mg/m(2)/day) starting on Day 1 of the first chemotherapy cycle
Number of subjects: 308

Group type: COMPARATOR
Intervention: Late radiotherapy (RT) with chemotherapy (fluorouracil 375 mg/m(2)/day and leucovorin 20 mg/m(2)/day) starting on Day 1 of the third chemotherapy cycle
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Early RT arm (for patients who underwent abdominoperineal resection)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Late RT arm (for patients who underwent abdominoperineal resection)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 308
Study: 18647255

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Health Related Quality of Life (HRQoL)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Access to General Practitioners
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Level of isolation
Number of subjects: 367
Study: 16739703

Group type: EXPERIMENTAL
Intervention: Relapsing Remitting Multiple Sclerosis (RRMS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Secondary Progressive Multiple Sclerosis (SPMS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 27
Study: 15311098

Group type: EXPERIMENTAL
Intervention: Combination therapy (increased use of antihypertensive medications)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers (CCBs)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 940

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Overall BP awareness and treatment
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Fatal and non-fatal cardiovascular (CV) events
Number of subjects: 940
Study: 11157432

Group type: EXPERIMENTAL
Intervention: Poor outcome group (bipolar disorder)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Good outcome group (bipolar disorder)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 44
Study: 9661022

Group type: EXPERIMENTAL
Intervention: ZDV (200 mg every 8 h) alone for 4 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg q6h) alone for 4 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ZDV with ritonavir for 4 days
Number of subjects: 18
Study: 8151265

Group type: EXPERIMENTAL
Intervention: Metformin, 850 mg b.i.d.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metoprolol CR, 100 mg o.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2575021

Group type: EXPERIMENTAL
Intervention: Beta adrenergic‐blocking agents administered in the acute phase of myocardial infarction
Number of subjects: 0
Study: 31168742

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model, 4 sessions of 90 minutes each
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 30648231

Group type: EXPERIMENTAL
Intervention: Chinese translation of the Cancer Survivor Profile for breast cancer (CSPro‐BC)
Number of subjects: 444
Study: 28486729

Group type: EXPERIMENTAL
Intervention: Vibration group (VIB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Non-vibration group (N-VIB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50